Navigation Links
Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
Date:8/15/2008

CORAL GABLES, Fla., Aug. 15 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results for the second quarter and six months ended June 30, 2008.

"We continue to progress with our clinical development program for CPP-109," stated Patrick J. McEnany, Catalyst's Chief Executive Officer. "In particular, we are actively enrolling and dosing subjects in our U.S. Phase II clinical trials evaluating CPP-109 as a treatment for cocaine and methamphetamine addiction. We expect to have top-line results from our cocaine trial and our methamphetamine trial in the first quarter of 2009 and the third quarter of 2009, respectively."

"Additionally, we expect to launch other Phase II trials this year in indications which could include binge eating disorder and alcohol dependence. As we previously discussed, it is likely that Catalyst will seek partners for these indications."

Second Quarter 2008 Results

For the quarter ended June 30, 2008, the Company reported a net loss of $2,377,440, or $0.19 per basic and diluted share, compared to a net loss of $1,208,130, or $0.10 per basic and diluted share for the same period in 2007. Second quarter 2008 results included non-cash charges relating to stock-based compensation in the amount of $123,208, compared to $182,233 in the same period in 2007. For the six months ended June 30, 2008, the Company reported a net loss of $3,961,487, or $0.32 loss per basic and diluted share, compared to a net loss of $2,460,208, or $0.20 loss per basic and diluted share, for the same period in 2007. Results for the first six months of 2008 included non-cash charges relating to stock-based compensation in the amount of $386,612, compared to $382,601 in
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Controlling the size of nanoclusters: First step in making new catalysts
2. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
3. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
4. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
5. Experiments reveal unexpected activity of fuel cell catalysts
6. Using catalysts to stamp nanopatterns without ink
7. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
8. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
9. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
10. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
11. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Wendel – recipient of a Regional Top Doctor Award for ... Surgeon Specialists for Nashville, TN – has released a new ... Hydration Booster, Retexturing Night Crème, and Anti-aging C Complex, all ... radiant appearance while protecting them from the sun’s harmful UV ... Dr. J. J. Wendel Plastic Surgery, we have developed a ...
(Date:7/29/2014)... 29, 2014 ... zur Erfassung biologischer Daten in Verbindung mit ... patentiert. Das LBS nimmt gleichzeitig mehrere Blutproben ... Patienten und sucht erhöhte biologische Aktivitäten in ... die Entdeckung und Entwicklung neuer Medikamente und ...
(Date:7/28/2014)... Reston, VA (PRWEB) July 28, 2014 ... leading nonprofit authority on the use of health IT ... its Health Plan Identifier (HPID) Workgroup has ... Between a Health Plan and Payer?” The HPID Workgroup, ... worked closely with the Centers for Medicare and Medicaid ...
(Date:7/28/2014)... 28, 2014 Proove Biosciences , ... be exhibiting data and research conducted through their latest ... Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. The ... Hyatt Regency, in Orlando, Florida. , The ... competence of physicians who care for patients suffering specificity ...
Breaking Biology Technology:Dr. J. J. Wendel Launches New Line of Skin Care Products 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2
... Shows No Thrombosis, Low MACE Rates ... Thirty Patients, ABBOTT PARK, Ill., March 13 ... first clinical trial of a,fully bioabsorbable drug eluting stent ... thrombosis, no clinically driven target,lesion revascularizations (retreatment of a ...
... BERKELEY, Calif., March 13 Nile Therapeutics,Inc. (OTC ... and,full year financial results for 2007. Participants may ... the investor relations section of,Nile,s website at ... company,s website until the next quarterly conference call., ...
... Unigene,Laboratories, Inc. (OTCBB: UGNE) announced that it ... release titled "Stonegate Report About Unigene,Laboratories Inc.", ... Company,s,policies and procedures, Unigene does not endorse, ... by analysts and unrelated third,parties. Any opinions, ...
Cached Biology Technology:The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 2The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 3The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 4Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3Unigene Restates Policy on Analyst Reports 2
(Date:7/29/2014)... affects 1 in 100,000 people characterized by a loss ... remains unknown, a new study by a team of researchers ... Germany and other European institutions confirms for the first time ... 6 July in Nature Genetics , is an important ... a sphincter in the lower esophagus opens, allowing food to ...
(Date:7/28/2014)... by the U.S. Food and Drug Administration (FDA) for ... bacterial pathogens inside human cells, including those that cause ... published in mBio , the online open-access journal ... way of identifying non-antibiotic drugs that could one day ... drugs on the list inhibit the growth of at ...
(Date:7/28/2014)... by the University of Arizona has sequenced the complete ... enhance scientists, and agriculturalists, understanding of the growing patterns ... of new rice varieties that are better able to ... hunger challenges. , The paper, "The genome sequence of ... independent domestication," was published online in Nature Genetics ...
Breaking Biology News(10 mins):Mysterious esophagus disease is autoimmune after all 2New route to identify drugs that can fight bacterial infections 2Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4
... Hospital have discovered a new genetic disease that can lead ... bile is missing, the liver cells are exposed to the ... a transformation of liver cells into connective tissue with a ... the cases of liver cirrhosis of unknown origin and open ...
... Meyskens, Jr., M.D., one of the "fathers" of ... to receive the seventh annual American Association for ... in Cancer Prevention Research. The award is ... to the field of cancer prevention research in ...
... Jewish Health have identified a simple gene-based blood test ... response to therapy than current tests. The test, a ... and help clear a backlog of promising medications now ... the results of a small "proof-of-principal" trial in the ...
Cached Biology News:Toxic bile damages the liver 2Meyskens honored with AACR-Prevent Cancer Foundation award 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 3
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... inhibitor that noncovalently binds and inactivates neutral pancreatic ... RNase 1, T1, T2, H, U1, U2 or ... inhibitor in that it has a more robust ... RNase in the absence of DTT or other ...
Biology Products: